Sepsis, an adverse auto-immune response to an infection often causing life-threatening complications, results in the highest mortality and treatment cost of any illness in US hospitals. Several immune biomarker levels, including Interleukin 6 (IL-6), have shown a high correlation to the onset and progression of sepsis. Currently, no technology diagnoses and stratifies sepsis progression using biomarker levels. This paper reports a microfluidic biochip platform to detect proteins in undiluted human plasma samples. The device uses a differential enumeration platform that integrates Coulter counting principles, antigen specific capture chambers, and micro size bead based immunodetection to quantify cytokines. This microfluidic biochip was validated as a potential point of care technology by quantifying IL-6 from plasma samples (n = 29) with good correlation (R² = 0.81) and agreement (Bland–Altman) compared to controls. In combination with previous applications, this point of care platform can potentially detect cell and protein biomarkers simultaneously for sepsis stratification.

中文翻译：

---

用于蛋白质电定量的微流控生物芯片平台†

败血症是对感染的不利的自身免疫反应，通常会导致危及生命的并发症，导致美国医院中任何疾病的死亡率和治疗费用最高。几种免疫生物标志物水平，包括白介素6（IL-6），已显示与败血症的发生和发展高度相关。当前，没有技术使用生物标志物水平来诊断败血症的进展并对其进行分层。本文报道了一种微流控生物芯片平台，用于检测未稀释的人类血浆样品中的蛋白质。该设备使用差分计数平台，该平台整合了库尔特计数原理，抗原特异性捕获室和基于微珠的免疫检测功能来量化细胞因子。通过对血浆样品中的IL-6进行定量，该微流控生物芯片已被验证为一种潜在的护理技术（与对照组相比，n = 29）具有良好的相关性（R ² = 0.81）和一致性（Bland–Altman）。结合以前的应用，此护理点平台可以潜在地同时检测细胞和蛋白质生物标志物，以进行脓毒症分层。